Health  Vol.2 No.1 , January 2010
A low dose of nicotine is sufficient to produce nicotine withdrawal in mice
ABSTRACT
The objective of our study was to investigate whether the chronic administration of a low dose of nicotine can be followed by a withdrawal syndrome at cessation of nicotine delivery. Pre-vious studies showed various results, depend-ing in the doses of nicotine, species, ways of administration and behavioural paradigms, but all emphasized a withdrawal effect on some or all of the following spontaneous behaviours: grooming, rearing, body shake or tremor, body scratching, abdominal constriction, jumping. However, it is not clear which behaviour is ex-actly altered, as a global behavioural index is most frequently used. This is not clear either if anxiety modulates the behavioral expression of withdrawal or which factors contribute to its locomotors effect, if any. To distant-angle these processes, we scored each of these behaviours individually before nicotine exposure, during continuous nicotine delivery and at cessation of nicotine delivery after precipitated withdrawal by mecamylamine injection. We also measured locomotor activity and anxiety levels in the same animals. We used a low dose of nicotine (2.4 mg/kg/day as free base) that has been pre-viously shown to produce nicotinic receptors up-regulation, both in the brain and in blood cells. With such a low dose, nicotine withdrawal didn’t affect locomotion nor anxiety levels but increased the number of rearing, jumping, and marginally, body-scratching. Other behaviours, classically considered to contribute to with-drawal syndrome, were unaffected, e.g., groom- ing, body or forelimb shakes. Our results show that anxiety may be dissociated from the be-havioural withdrawal syndrome. Also, the se-verity of the syndrome produced by nicotine withdrawal is qualitatively and quantitatively different from the one induced by other drugs of abuse and also by the one produced by nicotine at higher doses.

Cite this paper
nullMorgane, B. , Sandra, S. , Jean-Pierre, C. and Sylvie, G. (2010) A low dose of nicotine is sufficient to produce nicotine withdrawal in mice. Health, 2, 1-7. doi: 10.4236/health.2010.21001.
References
[1]   Chiara, Di G. (2000) Role of dopamine in the behavioural actions of nicotine related to addiction. Eur. J. Pharmacol, 393, 295-314.

[2]   Epping-Jordan, M.P., Watkins, S.S., Koob, G.F. and Markou, A. (1998) Dramatic decrease in brain reward function during nicotine withdrawal. Nature, 393, 76-79.

[3]   Rose, J.E. and Corrigall, W.A. (1997) Nicotine self-ad-ministration in animals and humans: Similarities and dif-ferences. Psychopharmacology, 130, 28-40.

[4]   Aston-Jones, G. and Harris, G.C. (2004) Brain substrates for increased drug seeking during protracted withdrawal. Neuropharmacol, 47, 167-179.

[5]   Stolerman, I.P. and Jarvis, M.J. (1995) The scientific case that nicotine is addictive. Psychopharmacology, 117, 2-10.

[6]   Malin, D.H., Lake, J.R., Newlin-Maultsby, P., Roberts, L.K., Lanier, J.G., Carter, V.A., Cunningham, J.S. and Wilson, O.B. (1992) Rodent model of nicotine abstinence syndrome. Pharmacol. Biochem. Behav., 43, 779-784.

[7]   Castané, A., Valjent, E., Ledent, C., Parmentier, M., Maldonado, R. and Valverde, O. (2002) Lack of CB1 cannabinoid receptors modifies nicotine behavioural re-sponses, but not nicotine abstinence. Neuropharmacology, 43, 857-867.

[8]   Isola, R., Vogelsberg, V., Wemlinger, T.A., Neff, N.H. and Hadjiconstantinou, M. (1999) Nicotine abstinence in the mouse. Br. Res., 850, 189-196.

[9]   Salas, R., Pieri, F., and Biasi, De M. (2004) Decreased signs of nicotine withdrawal in mice null for the 4 nico-tinic acetylcholine receptor subunit. J. Neurosci., 24, 10035-10039.

[10]   Salmon, A.M., Evrard, A., Damaj, I. and Changeux, J.P. (2004) Reduction of withdrawal signs after chronic nico-tine exposure of alpha-calcitonin gene-related peptide knock-out mice. Neurosci Lett., 360, 73-76.

[11]   Cormier, A., Paas, Y., Zini, R., Tillement, J.P., Lagrue, G., Changeux, J.P. and Grailhe, R. (2004) Long-term expo-sure to nicotine modulates the level and activity of ace-tylcholine receptors in white blood cells of smokers and model mice. Molec. Pharmacol, 66, 1712-1718.

[12]   Fung, Y.K., Schmid, M.J., Anderson, T.M. and Lau, Y.S. (1996) Effects of nicotine withdrawal on central dopa-minergic systems. Pharmacol. Biohem. Behav, 53, 635- 640.

[13]   Hildebrand, B.E., Nomikos, G.G., Bondjers, C., Nisell, M. and Svensson, T.H. (1997) Behavioural manifestations of the nicotine abstinence syndrome in the rat: Peripheral versus central mechanisms. Psychopharmacology, 129, 348-356.

[14]   Damaj, M.I., Kao, W. and Martin, B.R. (2003) Charac-terization of spontaneous and precipitated nicotine with-drawal in the mouse. J. Pharmacol. Exp. Ther. 307, 526-534.

[15]   Jonkman, S., Henry, B., Semenova, S. and Markou, A. (2005) Mild anxiogenic effects of nicotine withdrawal in mice. Eur. J. Pharmacol, 516, 40-45.

[16]   G?ddn?s, H., Pietil?, K. and Ahtee, L. (2000) Effects of chronic oral nicotine treatment and its withdrawal on lo-comotor activity and brain monoamines in mice. Behav. Br. Res, 113, 65-72.

[17]   Granon, S., Faure, P. and Changeux, J.P (2003) Executive and social behaviours under nicotinic receptor regulation. Proc Natl Acad Sci USA, 100, 9596-9601.

[18]   Helton, D.R., Modlin, D.L., Tizzano, J.P. and Rasmussen, K. (1993) Nicotine withdrawal: A behavioural assessment using schedule controlled responding, locomotor activity, and sensorimotor reactivity. Psychopharmacology, 113, 205-210.

[19]   Hildebrand, B.E., Panagis, G., Svensson, T.H. and Nomikos, G.G. (1999) Behavioural and biochemical manifestations of mecamylamine-precipitated nicotine withdrawal in the rat: Role of nicotinic receptors in the ventral tegmental area. Neuropsychopharmacology, 21, 560-574.

[20]   Malin, D.H., Lake, J.R., Carter, V.A., Cunningham, J.S., Hebert, K.M., Conrad, D.L. and Wilson, O.B. (1994) The nicotine antagonist mecamylamine precipitates nicotine abstinence syndrome in the rat. Psychopharmacology, 115, 180-184.

[21]   Lipkind, D., Sakov, A., Kafkafi, N., Elmer, G.I., Benjamini, Y. and Golani, I. (2004) New replicable anxiety-related measures of wall vs centre behaviour of mice in the open field. J. Appl. Physiol., 97, 347-59.

[22]   Crawley, J.N. (2000) What’s wrong with my mouse? Behavioural phenotyping of transgenic and knockout mice. John Wiley-Liss Publication.

[23]   Fujita, S., Adachi, K., Lee, J., Uchida, T., Koshikawa, N. and Cools, A.R. (2004) Decreased postsynaptic dopa-minergic and cholinergic functions in the ventrolateral striatum of spontaneously hypertensive rats. Eur. J. Pharmacol, 484, 75-82.

[24]   Carboni, E., Bortone, L., Giua, C. and Chiara, Di G. (2000) Dissociation of physical abstinence signs from changes in extra cellular dopamine in the nucleus accumbens and in the prefrontal cortex of nicotine dependent rats. Drug Alcohol Depend, 58, 93-102.

[25]   Rada, P., Jensen, K. and Hoebel, B.G. (2001) Effects of nicotine and mecamylamine-induced withdrawal on ex-tracellular dopmaine and acetylcholine in the rat nucleus accumbens. Psychopharmacology, 157, 105-110.

[26]   Maldonado, R. (2002) Study of cannabinoid dependence in animals. Pharm. Ther., 92, 153-164.

[27]   Kenny, P.J. and Markou, A. (2001) Neurobiology of the nicotine withdrawal syndrome. Pharmacol. Biochem. Behav., 70, 531-549.

[28]   Balerio, G.N., Aso, E., Berrendero, F., Murta, P. and Maldonado, R. (2004) D9-Tetrahydrocannabinol decreases somatic and motivations of nicotine withdrawal in mice. Eur. J. Neurosci, 20, 2737-2748.

[29]   Spielewoy, C. and Markou, A. (2004) Strain-specificity in nicotine attenuation of phencyclidine-induced disruption of prepulse inhibition in mice: Relevance to smoking in schizophrenia patients. Behav. Genet., 34, 343-354.

[30]   Berrettini, W.H. and Lerman, C.E. (2005) Pharmaco-therapy and pharmacogenetics of nicotine dependence. Am. J. Psychiatry, 162, 1441-1451.

 
 
Top